Rituximab/Bendamustine treatment of chronic lymphatic leukemia leads to sustained remission of antiphospholipid antibodies.

Rituximab/Bendamustine treatment of chronic lymphatic leukemia leads to sustained remission of antiphospholipid antibodies. Eur J Immunol. 2019 Mar 20;: Authors: Ames PR, Merashli M, Gentile F PMID: 30893471 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/30893471?dopt=Abstract

Source: European Journal of Immunology - March 19, 2019 Category: Allergy & Immunology Authors: Ames PR, Merashli M, Gentile F Tags: Eur J Immunol Source Type: research